The FY 2026 Inpatient Prospective Payment System (IPPS) proposed rule is expected soon, and many stakeholders will be watching for any updates to the New Technology Add-on Payment (NTAP) program. NTAP provides the opportunity for additional Medicare reimbursement for qualifying innovations. Securing NTAP status helps hospitals adopt innovative technologies for their patients by offsetting higher costs during the early years of commercialization. Centers for Medicare and Medicaid Services (CMS) decisions regarding NTAP have a significant impact for both hospitals and medical device and pharmaceutical companies, and play a key role in shaping reimbursement and market access strategies. Companies preparing to commercialize their product and looking to gain Medicare coverage will benefit from a thorough understanding of the latest NTAP policies and implications.
Read on as we explore the different pathways for NTAP eligibility, the associated criteria for each pathway, and the timeline and key dates to consider before applying. This +Insight is the first in a new series on the NTAP program. Subscribe to our mailing list to ensure you receive future updates.
